Randomized Phase II/III Trial of Second Line Chemotherapy Comparing CPT-11 Monotherapy Versus S-1/CPT-11 Combination for S-1 Refractory Gastric Cancer

Trial Profile

Randomized Phase II/III Trial of Second Line Chemotherapy Comparing CPT-11 Monotherapy Versus S-1/CPT-11 Combination for S-1 Refractory Gastric Cancer

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Jun 2015

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Jan 2014 Primary endpoint 'Overall-survival-duration' has not been met.
    • 18 Jan 2014 Results presented at the 2014 Gastrointestinal Cancers Symposium.
    • 11 Sep 2013 The Japan Clinical Cancer Research Organization (JACCRO) will further investigate the data and make a detailed announcement of the results at a medical conference in 2014, according to a Taiho Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top